全文获取类型
收费全文 | 379篇 |
免费 | 25篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 18篇 |
基础医学 | 51篇 |
口腔科学 | 3篇 |
临床医学 | 27篇 |
内科学 | 118篇 |
皮肤病学 | 3篇 |
神经病学 | 25篇 |
特种医学 | 5篇 |
外科学 | 22篇 |
综合类 | 3篇 |
预防医学 | 21篇 |
眼科学 | 1篇 |
药学 | 31篇 |
中国医学 | 2篇 |
肿瘤学 | 73篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 12篇 |
2021年 | 13篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 10篇 |
2016年 | 9篇 |
2015年 | 8篇 |
2014年 | 14篇 |
2013年 | 16篇 |
2012年 | 15篇 |
2011年 | 28篇 |
2010年 | 18篇 |
2009年 | 21篇 |
2008年 | 14篇 |
2007年 | 26篇 |
2006年 | 23篇 |
2005年 | 23篇 |
2004年 | 29篇 |
2003年 | 21篇 |
2002年 | 33篇 |
2001年 | 6篇 |
2000年 | 1篇 |
1999年 | 7篇 |
1998年 | 3篇 |
1997年 | 9篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1983年 | 4篇 |
1980年 | 2篇 |
1956年 | 1篇 |
排序方式: 共有405条查询结果,搜索用时 0 毫秒
401.
Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo 总被引:3,自引:0,他引:3
Inoue K Umehara T Ruegg UT Yasui F Watanabe T Yasuda H Dumont JM Scalfaro P Yoshiba M Kohara M 《Hepatology (Baltimore, Md.)》2007,45(4):921-928
Cyclosporin A (CsA) inhibits replication of the HCV subgenomic replicon, and this effect is believed to not be mediated by its immunosuppressive action. We found that DEBIO-025, a novel non-immunosuppressive cyclophilin inhibitor derived from CsA, inhibited HCV replication in vitro more potently than CsA. We also examined the inhibitory effect of DEBIO-025 on naive HCV genotypes 1a or 1b in vivo using chimeric mice with human hepatocytes. These mice were treated for 14 days with DEBIO-025, pegylated-interferon alpha-2a (Peg-IFN), a combination of either drugs, or CsA in combination with Peg-IFN. In mice treated with Peg-IFN, serum HCV RNA levels decreased approximately 10-fold whereas DEBIO-025 treatment alone did not induce any significant change. In mice treated with both DEBIO-025 and Peg-IFN, HCV RNA levels decreased more than 100-fold. All mice treated with Peg-IFN combined with CsA died within 4 days. The combination treatment of DEBIO-025 and Peg-IFN reduced HCV RNA levels and core protein expression in liver, indicating that the HCV RNA levels reduction in serum was attributable to intrahepatic inhibition of HCV replication. CONCLUSION: We demonstrated that DEBIO-025 was better tolerated than CsA, and that its anti-HCV effect appeared to be synergistic in combination with Peg-IFN in vivo. 相似文献
402.
403.
Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
Keiji Konishi Hidenori Nakagawa Tomohiro Asaoka Yu Kasamatsu Tetsushi Goto Michinori Shirano 《Medicine》2022,101(42)
To investigate the prevalence of sarcopenia among people living with HIV (PLWH) in Japan and analyze the relationship between HIV infection and ART effects on the body composition of Japanese PLWH for more appropriate drug selection and lifestyle guidance. Cross-sectional observational study. We included male patients aged ≥ 60 years whose body composition was measured by InBody 570 body composition analyzer during outpatient visits. Patients were classified by body shape based on body mass index (BMI) and body fat percentage measurements and by tenofovir alafenamide administration. Hidden obesity is a condition wherein the BMI is within the standard range but the body fat percentage is higher than the reference. Patients with low muscle mass and strength were considered to have sarcopenia, whereas those with only low muscle strength were considered to have pre-sarcopenia. In total, 87 patients were included. Based on body shape determined by BMI and body fat percentage, most patients had hidden obesity (40 patients, 46.0%). Sarcopenia was detected in 9 patients (10.3%) and pre-sarcopenia in 14 patients (16.1%). The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group. Hidden obesity is a risk for lifestyle diseases. It is important to recognize it based on body composition measurements because it can be missed by BMI measurement alone. Tenofovir alafenamide therapy increases skeletal muscle mass, which may result in the prevention of sarcopenia. To clarify how TAF affects the development of sarcopenia and lifestyle diseases, future studies on a larger cohort are warranted. 相似文献
404.
405.
Michinori Ogura Kazuhito Yamamoto Yasuo Morishima Masashi Wakabayashi Kensei Tobinai Kiyoshi Ando Naokuni Uike Mitsutoshi Kurosawa Hiroshi Gomyo Masafumi Taniwaki Kisato Nosaka Norifumi Tsukamoto Tatsu Shimoyama Noriko Fukuhara Yoshihiro Yakushijin Kazunori Ohnishi Kana Miyazaki Yoshihiro Kameoka Nobuyuki Takayama Ichiro Hanamura Hirofumi Kobayashi Kensuke Usuki Naoki Kobayashi Kazuma Ohyashiki Takahiko Utsumi Kyoya Kumagai Dai Maruyama Ken Ohmachi Yoshihiro Matsuno Shigeo Nakamura Tomomitsu Hotta Kunihiro Tsukasaki Hirokazu Nagai 《Cancer science》2023,114(8):3461-3465